MSD-Moderna Phase III readout backs personalised mRNA neoantigen combination adjuvant therapy for melanoma

2026-08-20T10:27:00

3d-rendering-ribosome-messenger-rna-mrna

Source:

First combination regimen to demonstrate significant reduction in recurrence risk in completely resected stage IIB-IV melanoma compared to Keytruda alone as adjuvant treatment.

Intismeran autogene in combination with anti-PD-1 therapy Keytruda (pembrolizumab) can facilitate longer cancer-free survival in completely resected stage IIB-IV melanoma, new Phase III data shows.

The findings from MSD and Moderna represent the first…

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

  • Unlimited access to industry intelligence that can make a difference to your business
  • A weekly newsletter keeping the most vital information at the front of your thinking
  • Exclusive invitations to powerful webinars and events featuring high profile experts
  • Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member